Corvus Pharmaceuticals (CRVS) PT Raised to $13 at Mizuho
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/3/2026
- Nasdaq ends higher as AI heavyweights rebound ahead of midterm results
- Apple shares slip amid guidance for tightening margins, slowing services growth
- Rising shorts cool U.S. large-cap positioning, cutting liquidation risk: Citi
- Apple's 'unprecedented' memory warning adds fuel to wobbly Micron, SK hynix trade
- Palantir raises 2026 revenue outlook after quarterly revenue nearly doubles on AI
Tweet
Share
E-mailGet Alerts CRVS Hot Sheet
Price: $9.83 +1.34%
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Rating Summary:
14 Buy, 0 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 15 | Down: 22 | New: 15
Join SI Premium – FREE
Mizuho analyst Graig Suvannavejh raised the price target on Corvus Pharmaceuticals (NASDAQ: CRVS) to $13.00 (from $11.00) while maintaining a Outperform rating.
You May Also Be Interested In
- Hagerty Inc. (HGTY) PT Raised to $20 at Oppenheimer
- Expedia (EXPE) PT Raised to $204 at Stifel
- UBS Downgrades Alphatec Holdings (ATEC) to Neutral
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
